Skyrizi denied by insurance? How to appeal
The short answer
Skyrizi denials usually turn on prior authorization: the plan wants proof of the diagnosis, a specialist prescriber, and for psoriasis, a trial of an older drug like methotrexate first. Get the plan's written criteria, then have your doctor answer each one with dated records. If Skyrizi is not on your plan's drug list, ask for a formulary exception.
- StartThe denial letterFind what was denied, the reason, and the deadline to appeal.
- Step 1Appeal to your planMost plans give you 60 to 180 days to ask. The plan reviews its own decision.
- Step 2Go outside the planIf it says no again, someone outside the plan can decide: an independent reviewer, a hearing, or a federal office.
Can’t wait? If waiting could seriously harm your health, ask for a fast appeal. Most plans must decide within 72 hours.
What Skyrizi is approved for
Skyrizi (risankizumab) blocks interleukin-23. As of November 2026 its FDA label lists four uses:
- Moderate to severe plaque psoriasis in adults and children 6 and older who are candidates for systemic therapy or light therapy.
- Active psoriatic arthritis in adults and children 6 and older.
- Moderately to severely active Crohn's disease in adults.
- Moderately to severely active ulcerative colitis in adults.
Why plans deny Skyrizi
No trial of an older drug. For psoriasis, one insurer's national policy asks that the patient tried at least one traditional systemic agent for at least 3 months, such as methotrexate, cyclosporine or acitretin, unless they could not tolerate it. Patients who already tried another biologic, Otezla or Sotyktu do not have to step back.
Missing specialist or dosing plan. For Crohn's disease, the same policy requires a gastroenterologist and a plan for IV induction doses within 3 months of starting the injections.
The renewal lacked proof. Renewals require that the patient experienced a beneficial clinical response by at least one objective measure, such as lab markers or scope results for Crohn's.
Plan preference. Some plans list Skyrizi as preferred and others do not. In one insurer's national formulary, Skyrizi is a Step 1 preferred product for psoriasis, psoriatic arthritis and inflammatory bowel disease, but your plan may differ.
Reading the denial
Job-based plans must name the specific plan provision behind a denial, and you can ask for a free copy of the criteria. "Criteria not met" means the plan wanted more medical proof; see prior authorization denials. "Step therapy" or "try a preferred product first" means the plan wants another drug tried; see step therapy denials. "Non-formulary" means Skyrizi is not on the drug list, which calls for a formulary exception. Check your plan's drug list to see what it prefers.
What your doctor's letter should document
Ask for a letter of medical necessity that answers each criterion, in order, with dated records:
- The diagnosis, its diagnosis code, and how severe it is, such as body surface area for psoriasis or scope and lab results for Crohn's or colitis.
- Every prior treatment: drug, dose, start and stop dates, and why it stopped.
- Any reason an older drug is unsafe for you, such as liver problems with methotrexate.
- The specialist's name and role.
- For renewals, measurements from before Skyrizi and now.
Ask the plan for the written criteria it used. Job-based plans must name the specific plan provision behind a denial and give you a free copy of any criteria they relied on. File the internal appeal within 180 days of the denial.
If Skyrizi is not on the drug list, ask for a formulary exception instead of, or alongside, the appeal. Your doctor generally confirms that covered drugs have not worked, will not work as well, or are likely to cause harm. Individual and small-group plans must decide a standard request within 72 hours and an expedited one within 24 hours, and a denial can go to an independent reviewer. See formulary exception letters.
If the plan upholds a denial that turned on medical judgment, you can ask for external review within 4 months of the final decision. Your insurer has to accept the reviewer’s decision.
Medicare, Medicaid and manufacturer help
With a Medicare drug plan, ask for a coverage determination or exception. Your prescriber must provide a statement explaining the medical reason. The plan must decide within 72 hours, or 24 hours if expedited, and Part D exceptions can also cover step therapy and dose limits. You have 65 days to appeal a denial. See Part D appeals.
When a clinic gives the drug, Medicare may pay under Part B instead. Medicare.gov says Part B usually covers drugs you wouldn’t typically give to yourself, like those given in a doctor's office, and most injectable and infused drugs when a licensed provider gives them. Ask the clinic which part of Medicare it is billing, because the appeal path differs. See Original Medicare appeals.
State Medicaid programs may require prior authorization for any covered drug. See Medicaid appeals.
AbbVie runs Skyrizi Complete, which offers support, possible ways to save and help with insurance questions.
Questions people ask
Do I have to try methotrexate before Skyrizi?
For psoriasis, many plans ask. One policy requires a 3-month trial of a traditional systemic drug unless you could not tolerate it, had a reason not to take methotrexate, or already tried a biologic.
Why was my Skyrizi renewal denied?
Renewals usually need proof the drug is working. One policy requires a beneficial clinical response from baseline. Ask your doctor to document specific changes with dates.
Insurance stopped covering Skyrizi after I'd been on it. What can I do?
First find out why: a lapsed prior authorization, a renewal that asked for proof the drug is working, or a drug-list change. Ask your doctor to resubmit with current records. In individual and small-group plans, being in the middle of a course of treatment on a non-formulary drug qualifies for a 24-hour expedited exception. Medicare drug plans must offer a temporary supply in the first 90 days under a new plan, and that process also covers current enrollees affected by formulary changes.
What if my Skyrizi appeal is denied?
If the denial turned on medical judgment, you can ask for external review by an independent reviewer within 4 months of the plan's final decision. A denied formulary exception in an individual or small-group plan can also go to independent review. With Medicare Part D, if the plan upholds its denial you have 60 days to ask a Part D Independent Review Entity to reconsider; see Part D appeals.
Sources
- National Library of Medicine (DailyMed): SKYRIZI (risankizumab-rzaa) prescribing information (DailyMed)
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of
- Cigna Healthcare: Inflammatory Conditions – Skyrizi Subcutaneous Prior Authorization Policy (Cigna National Formulary, review date 06/03/2026)
Patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant
- Cigna Healthcare: Inflammatory Conditions Preferred Specialty Management Policy for National Preferred and Basic Formularies (Cigna, review date 07/29/2026)
this program requires trial(s) of the Preferred Product(s) according to the table below when clinically appropriate, prior to the approval of the Non-Preferred Products
- eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedure
Reference to the specific plan provisions on which the determination is based
- HealthCare.gov: Getting prescription medications
Visit your insurer’s website to review a list of prescriptions your plan covers
- HealthCare.gov: Internal appeals
You must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
- eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefits
A health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
- HealthCare.gov: External Review
You must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied.
- Medicare.gov: Appeals in a Medicare drug plan
If you're asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
- eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinations
but no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinations
but no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions process
An exception to a plan's coverage policy that causes a Part D prescription drug not to be covered because of cost utilization tools, such as a requirement for step therapy, dosage limitations, or therapeutic substitution.
- Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugs
A State may subject to prior authorization any covered outpatient drug
- Medicare.gov: Prescription drugs (outpatient)
Usually, Part B covers drugs you wouldn't typically give to yourself, like those you get at a doctor's office or in a hospital outpatient setting.
- AbbVie: Skyrizi Complete
Skyrizi Complete offers support, potential ways to save, answers to your treatment and insurance questions
- eCFR (Office of the Federal Register): 42 CFR 423.120 -- Access to covered Part D drugs
Ensure access to a temporary supply of drugs within the first 90 days of coverage under a new plan.
This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.